Wednesday, 16 June 2010

Biogen Idec Announces Enrollment of First Patient in Phase II BG-12 Combination Trial in Multiple Sclerosis

CAMBRIDGE, Mass., Jun 15, 2010 (BUSINESS WIRE) -- Biogen Idec /quotes/comstock/15*!biib/quotes/nls/biib (BIIB 48.12, +1.33, +2.84%) today announced enrollment of the first patient in a multicenter Phase II clinical trial designed to evaluate its investigational oral therapy BG-12 (dimethyl fumarate) in combination with commonly used first-line treatments in patients with relapsing-remitting multiple sclerosis (RRMS). The trial, called EXPLORE, will evaluate the safety and tolerability of BG-12 when administered with beta interferons (IFNB) or glatiramer acetate (GA) to patients who continue to have evidence of disease activity despite receiving consistent monotherapy for at least a year. Efficacy endpoints will also be assessed in a subset of patients.